{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:57:06Z","timestamp":1793224626245,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s12325-014-0175-z","type":"journal-article","created":{"date-parts":[[2014,12,22]],"date-time":"2014-12-22T12:52:50Z","timestamp":1419252770000},"page":"31-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":225,"title":["A Review of Uric Acid, Crystal Deposition Disease, and Gout"],"prefix":"10.1007","volume":"32","author":[{"given":"Fernando","family":"Perez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,23]]},"reference":[{"key":"175_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","volume":"26","author":"T Bardin","year":"2014","unstructured":"Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014;26:186\u201391.","journal-title":"Curr Opin Rheumatol"},{"key":"175_CR2","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conagham P, Gerster J, et al. EULAR evidence based recommendations for gout Part II. Management. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312\u201324.","journal-title":"Ann Rheum Dis"},{"key":"175_CR3","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64:1431\u201346.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"175_CR4","author":"P Richette","year":"2014","unstructured":"Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;. doi: 10.1038\/nrrheum.2014.124 .","journal-title":"Nat Rev Rheumatol"},{"key":"175_CR5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.berh.2010.10.004","volume":"24","author":"EU Smith","year":"2010","unstructured":"Smith EU, Diaz-Torne C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24:811\u201327.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"175_CR6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","volume":"73","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73:177\u201382.","journal-title":"Ann Rheum Dis"},{"key":"175_CR7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894\u2013900.","journal-title":"Circulation"},{"key":"175_CR8","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","volume":"168","author":"E Krishnan","year":"2008","unstructured":"Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168:1104\u201310.","journal-title":"Arch Intern Med"},{"key":"175_CR9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/qjmed\/hct083","volume":"106","author":"AG Stack","year":"2013","unstructured":"Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ, et al. Independent and conjoint associations of gout and hyperuricemia with total and cardiovascular mortality. QJM. 2013;106:647\u201358.","journal-title":"QJM"},{"key":"175_CR10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","volume":"131","author":"BF Culleton","year":"1999","unstructured":"Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999;131:7\u201313.","journal-title":"Ann Intern Med"},{"key":"175_CR11","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125:679\u201387.","journal-title":"Am J Med"},{"key":"175_CR12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/acr.20344","volume":"63","author":"PC Grayson","year":"2011","unstructured":"Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:102\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"175_CR13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","volume":"41","author":"RJ Johnson","year":"2003","unstructured":"Johnson RJ, Kang DH, Feig DI, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183\u201390.","journal-title":"Hypertension"},{"key":"175_CR14","doi-asserted-by":"crossref","first-page":"F710","DOI":"10.1152\/ajprenal.00454.2007","volume":"294","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Tapia E, Bautista-Garcia P, Soto V, Vila-Casado C, Vega-Campos IP, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294:F710\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"key":"175_CR15","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1038\/ncomms5642","volume":"5","author":"BJ DeBosch","year":"2014","unstructured":"DeBosch BJ, Kluth O, Sch\u00fcrmann A, Moley K. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642. doi: 10.1038\/ncomms5642 .","journal-title":"Nat Commun"},{"key":"175_CR16","first-page":"925","volume":"300","author":"DI Feig","year":"2008","unstructured":"Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. A randomized trial. JAMA. 2008;300:925\u201332.","journal-title":"JAMA"},{"key":"175_CR17","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","volume":"60","author":"B Soletsky","year":"2012","unstructured":"Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolecents. Hypertension. 2012;60:1148\u201356.","journal-title":"Hypertension"},{"key":"175_CR18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2369-12-31","volume":"12","author":"M Kawashima","year":"2011","unstructured":"Kawashima M, Wada K, Ohta H, Terawaki H, Aizawa Y. Association between asymptomatic hyperuricemia and new-onset chronic kidney disease in Japanese male workers: a long-term retrospective cohort study. BMC Nephrol. 2011;12:31. doi: 10.1186\/1471-2369-12-31 .","journal-title":"BMC Nephrol"},{"key":"175_CR19","author":"L Grimaldi-Bensouda","year":"2012","unstructured":"Grimaldi-Bensouda L, Alperovitch A, Aubrun E, Danchin N, Rossignol M, Abenhaim L, et al. Impact of allopurinol on risk of myocardial infarction. Ann Rheum Dis. 2012. doi: 10.1136\/annrheumdis-2012-202972 (Epub ahead of print).","journal-title":"Ann Rheum Dis"},{"key":"175_CR20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1365-2125.2010.03887.x","volume":"71","author":"L Wei","year":"2011","unstructured":"Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol. 2011;71:600\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"175_CR21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semarthrit.2006.08.001","volume":"36","author":"W Grassi","year":"2006","unstructured":"Grassi W, Meenagh G, Pascual E, Filippucci E. \u201cCrystal Clear\u201d-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum. 2006;36:197\u2013202.","journal-title":"Semin Arthritis Rheum"},{"key":"175_CR22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/rheumatology\/kem058","volume":"46","author":"RG Thiele","year":"2007","unstructured":"Thiele RG, Schlesinger N. Ultrasonography is a reliable, non-invasive method for diagnosing gout. Rheumatology. 2007;46:1116\u201321.","journal-title":"Rheumatology"},{"key":"175_CR23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/ajcp\/91.2.190","volume":"91","author":"DG Palmer","year":"1989","unstructured":"Palmer DG, Highton J, Hessian PA. Development of the gout tophus. An hypothesis. Am J Clin Pathol. 1989;91:190\u20135.","journal-title":"Am J Clin Pathol"},{"key":"175_CR24","author":"HK Choi","year":"2009","unstructured":"Choi HK, Al-Arfaj A, Eftekhari A, Munk PL, Shojania K, Reid G, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis. 2009;. doi: 10.1136\/ard.2008.099713 .","journal-title":"Ann Rheum Dis"},{"key":"175_CR25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","volume":"82","author":"EW Campion","year":"1987","unstructured":"Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med. 1987;82:421\u20136.","journal-title":"Am J Med"},{"key":"175_CR26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2011.154997","volume":"71","author":"E Miguel De","year":"2011","unstructured":"De Miguel E, Puig JG, CastilloC, Peiteado D, Torres RJ, Martin-Mola E. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Ann Rheum Dis. 2011;71:157\u20138.","journal-title":"Ann Rheum Dis"},{"key":"175_CR27","author":"RG Howard","year":"2011","unstructured":"Howard RG, Pillinger MH, Gyftopoulos S, Thiele RG, Swearingen CJ, Samuels J. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res (Hoboken). 2011;. doi: 10.1002\/acr.20527 .","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"175_CR28","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/ar3223","volume":"13","author":"C Pineda","year":"2011","unstructured":"Pineda C, Amezcua-Guerra LM, Solano C, Rodriguez-Henriquez P, Hernandez-Diaz C, Vargas A, et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther. 2011;13:R4.","journal-title":"Arthritis Res Ther"},{"key":"175_CR29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/15257770802136040","volume":"27","author":"JG Puig","year":"2008","unstructured":"Puig JG, de Miguel E, Castillo MC, Rocha AL, Martinez MA, Torres RJ. Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids. 2008;27:592\u20135.","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"175_CR30","doi-asserted-by":"crossref","first-page":"756","DOI":"10.7326\/0003-4819-131-10-199911160-00007","volume":"131","author":"E Pascual","year":"1999","unstructured":"Pascual E, Batlle-Gualda E, Martinez A, Rosas J, Vela P. Synovial fluid analysis for diagnosis of intercritical gout. Ann Intern Med. 1999;131:756\u20139.","journal-title":"Ann Intern Med"},{"key":"175_CR31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/nm.3547","volume":"20","author":"C Schauer","year":"2014","unstructured":"Schauer C, Janko C, Munoz LE, Zhao Y, Kienh\u00f6fer D, et al. Aggregated neutrophil extracellular traps limit imflammation by degrading cytokines and chemokines. Nat Med. 2014;20:511\u20137.","journal-title":"Nat Med"},{"key":"175_CR32","author":"E Naredo","year":"2013","unstructured":"Naredo E, Uson J, Jimenez-Palop M, Martinez A, Vicente E, Brito E, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis. 2013;. doi: 10.1136\/annrheumdis-2013-203487 (Epub ahead of print).","journal-title":"Ann Rheum Dis"},{"key":"175_CR33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2012-202786","volume":"72","author":"N Dalbeth","year":"2013","unstructured":"Dalbeth N, Kalluru R, Aati O, Horne A, Doyle AJ, McQueen FM. Tendon involvement in the feet of patients with gout: a dual-energy CT study. Ann Rheum Dis. 2013;72:1545\u20138.","journal-title":"Ann Rheum Dis"},{"key":"175_CR34","doi-asserted-by":"crossref","first-page":"R165","DOI":"10.1186\/ar3913","volume":"14","author":"N Dalbeth","year":"2012","unstructured":"Dalbeth N, Milligan A, Doyle AJ, Clark B, McQueen FM. Characterization of new bone formation in gout: a quantitative site-by-site analysis using plain radiography and computed tomography. Arthritis Res Ther. 2012;14:R165.","journal-title":"Arthritis Res Ther"},{"key":"175_CR35","author":"N Dalbeth","year":"2008","unstructured":"Dalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, et al. Mechanisms of bone erosions in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis. 2008;. doi: 10.1136\/ard.2008.094201 .","journal-title":"Ann Rheum Dis"},{"key":"175_CR36","author":"N Dalbeth","year":"2014","unstructured":"Dalbeth N, Aati O, Kalluru R, Gamble GD, Horne A, Doyle AJ, et al. Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study. Ann Rheum Dis. 2014;. doi: 10.1136\/annrheumdis-2013-204273 (Epub ahead of print).","journal-title":"Ann Rheum Dis"},{"key":"175_CR37","author":"A Ogdie","year":"2014","unstructured":"Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis. 2014;. doi: 10.1136\/annrheumdis-2014-205431 (Epub ahead of print).","journal-title":"Ann Rheum Dis"},{"key":"175_CR38","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3899\/jrheum.111517","volume":"39","author":"RM Konatalapalli","year":"2012","unstructured":"Konatalapalli RM, Lumezanu E, Jelinek JS, Murphey MD, Wang H, Weinstein A. Correlates of axial gout: a cross-sectional study. J Rheumatol. 2012;39:1445\u20139.","journal-title":"J Rheumatol"},{"key":"175_CR39","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3899\/jrheum.110477","volume":"38","author":"YJ Poh","year":"2011","unstructured":"Poh YJ, Dalbeth N, Doyle A, McQueen FM. Magnetic resonance imaging bone edema is not a major feature of gout unless there is concomitant osteomyelitis: 10-year findings from a high-prevalence population. J Rheumatol. 2011;38:2475\u201381.","journal-title":"J Rheumatol"},{"key":"175_CR40","first-page":"1888","volume":"34","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol. 2007;34:1888\u201393.","journal-title":"J Rheumatol"},{"key":"175_CR41","author":"RG Thiele","year":"2009","unstructured":"Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int. 2009;. doi: 10.1007\/s00296-009-1002-8 .","journal-title":"Rheumatol Int"},{"key":"175_CR42","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765\u201370.","journal-title":"Ann Rheum Dis"},{"key":"175_CR43","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","volume":"63","author":"F Perez-Ruiz","year":"2011","unstructured":"Perez-Ruiz F, Herrero-Beites AM, Carmona L. A two-stage approach to the treatment of hyperuricemia in gout: the \u201cDirty Dish\u201d hypothesis. Arthritis Rheum. 2011;63:4002\u20136.","journal-title":"Arthritis Rheum"},{"key":"175_CR44","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","volume":"72","author":"F Rees","year":"2013","unstructured":"Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis. 2013;72:826\u201330.","journal-title":"Ann Rheum Dis"},{"key":"175_CR45","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64:1447\u201361.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"175_CR46","first-page":"ii9","volume":"49","author":"F Perez-Ruiz","year":"2009","unstructured":"Perez-Ruiz F. Treating to target: an strategy to cure gout. Rheumatology. 2009;49:ii9\u201312.","journal-title":"Rheumatology"},{"key":"175_CR47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.rdc.2014.01.003","volume":"40","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz F, Castillo E, Chinchilla SP, Herrero-Beites AM. Clinical manifestations and diagnosis of gout. Rheum Dis Clin North Am. 2014;40:193\u2013206.","journal-title":"Rheum Dis Clin North Am"},{"key":"175_CR48","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","volume":"57","author":"F Perez-Ruiz","year":"2007","unstructured":"Perez-Ruiz F, Liot\u00e9 F. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum. 2007;57:1324\u20138.","journal-title":"Arthritis Rheum"},{"key":"175_CR49","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","volume":"47","author":"F Perez-Ruiz","year":"2002","unstructured":"Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356\u201360.","journal-title":"Arthritis Rheum"},{"key":"175_CR50","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","volume":"55","author":"F Perez-Ruiz","year":"2006","unstructured":"Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum. 2006;55:786\u201390.","journal-title":"Arthritis Rheum"},{"key":"175_CR51","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","volume":"26","author":"MK Reinders","year":"2007","unstructured":"Reinders MK, Van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007;26:1459\u201365.","journal-title":"Clin Rheumatol"},{"key":"175_CR52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/annrheumdis-2012-eular.2827","volume":"71","author":"F Perez Ruiz","year":"2012","unstructured":"Perez Ruiz F, Sundy J, Krishnan E, Hingorani V, Welp J, Rodgers T, et al. Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol-refractory gout patients: results from a randomized, blinded, placebo controlled, phase 2B extension study. Ann Rheum Dis. 2012;71:439.","journal-title":"Ann Rheum Dis"},{"key":"175_CR53","author":"R Fleischmann","year":"2014","unstructured":"Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. Rheumatology (Oxford). 2014;. doi: 10.1093\/rheumatology\/ket487 .","journal-title":"Rheumatology (Oxford)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-014-0175-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T02:29:34Z","timestamp":1498184974000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-014-0175-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,23]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["175"],"URL":"https:\/\/doi.org\/10.1007\/s12325-014-0175-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,23]]}}}